Alpha 2.0

» Articles » PMID: 20068138

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

Overview

Overview

Journal Diabetes

Specialty Endocrinology

Date 2010 Jan 14

PMID 20068138

Citations 248

Authors

Authors

Masayuki Arakawa

Tomoya Mita

Kosuke Azuma

Chie Ebato

Hiromasa Goto

Takashi Nomiyama

Yoshio Fujitani

Takahisa Hirose

Ryuzo Kawamori

Hirotaka Watada

Affiliations

Affiliations

Soon will be listed here.

Abstract

Objective: Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4 has direct beneficial effects on the cardiovascular system. However, their effects on atherosclerogenesis have not been elucidated. The aim of this study was to investigate the effects of GLP-1 on accumulation of monocytes/macrophages on the vascular wall, one of the earliest steps in atherosclerogenesis.

Research Design And Methods: After continuous infusion of low (300 pmol . kg(-1) . day(-1)) or high (24 nmol . kg(-1) . day(-1)) dose of exendin-4 in C57BL/6 or apolipoprotein E-deficient mice (apoE(-/-)), we evaluated monocyte adhesion to the endothelia of thoracic aorta and arteriosclerotic lesions around the aortic valve. The effects of exendin-4 were investigated in mouse macrophages and human monocytes.

Results: Treatment with exendin-4 significantly inhibited monocytic adhesion in the aortas of C57BL/6 mice without affecting metabolic parameters. In apoE(-/-) mice, the same treatment reduced monocyte adhesion to the endothelium and suppressed atherosclerogenesis. In vitro treatment of mouse macrophages with exendin-4 suppressed lipopolysaccharide-induced mRNA expression of tumor necrosis factor-alpha and monocyte chemoattractant protein-1, and suppressed nuclear translocation of p65, a component of nuclear factor-kappaB. This effect was reversed by either MDL-12330A, a cAMP inhibitor or PKI(14-22), a protein kinase A-specific inhibitor. In human monocytes, exendin-4 reduced the expression of CD11b.

Conclusions: Our data suggested that GLP-1 receptor agonists reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages, and that this effect may contribute to the attenuation of atherosclerotic lesion by exendin-4.

Citing Articles

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF).

Hullon D, Subeh G, Volkova Y, Janiec K, Trach A, Mnevets R Cardiovasc Diabetol. 2025; 24(1):70.

PMID: 39920668 PMC: 11806760. DOI: 10.1186/s12933-025-02607-w.

A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure.

Gul U, Aung T, Martin M, Farrukh D, Shah P, Lovely Z Cureus. 2025; 16(12):e76519.

PMID: 39872560 PMC: 11771532. DOI: 10.7759/cureus.76519.

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.

Lu C, Xu C, Yang J Medicina (Kaunas). 2025; 61(1).

PMID: 39858999 PMC: 11767243. DOI: 10.3390/medicina61010017.

Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials.

Zhang Y, Li Z, Hao Y Eur J Med Res. 2025; 30(1):13.

PMID: 39773332 PMC: 11706166. DOI: 10.1186/s40001-024-02241-4.

Effect of physical exercise on metabolism in patients with atrial fibrillation.

Wang Y, Weng S, Xia C, Xu T, Song X, Wang F Front Cardiovasc Med. 2025; 11:1502620.

PMID: 39749313 PMC: 11693651. DOI: 10.3389/fcvm.2024.1502620.

References

1.

Kobayashi M, Inoue K, Warabi E, Minami T, Kodama T . A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb. 2005; 12(3):138-42. DOI: 10.5551/jat.12.138. View

2.

Gu L, Okada Y, Clinton S, Gerard C, Sukhova G, Libby P . Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998; 2(2):275-81. DOI: 10.1016/s1097-2765(00)80139-2. View

3.

Kumashiro N, Tamura Y, Uchida T, Ogihara T, Fujitani Y, Hirose T . Impact of oxidative stress and peroxisome proliferator-activated receptor gamma coactivator-1alpha in hepatic insulin resistance. Diabetes. 2008; 57(8):2083-91. PMC: 2494675. DOI: 10.2337/db08-0144. View

4.

Brubaker P, Drucker D . Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004; 145(6):2653-9. DOI: 10.1210/en.2004-0015. View

5.

Greig N, Holloway H, De Ore K, Jani D, Wang Y, Zhou J . Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia. 1999; 42(1):45-50. DOI: 10.1007/s001250051111. View

6.

Liu H, Dear A, Knudsen L, Simpson R . A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009; 201(1):59-66. DOI: 10.1677/JOE-08-0468. View

7.

Delgado M, Ganea D . Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem. 2000; 276(1):369-80. DOI: 10.1074/jbc.M006923200. View

8.

Yamada H, Yoshida M, Nakano Y, Suganami T, Satoh N, Mita T . In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2008; 28(12):2173-9. DOI: 10.1161/ATVBAHA.108.171736. View

9.

Baggio L, Drucker D . Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132(6):2131-57. DOI: 10.1053/j.gastro.2007.03.054. View

10.

Ban K, Noyan-Ashraf M, Hoefer J, Bolz S, Drucker D, Husain M . Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008; 117(18):2340-50. DOI: 10.1161/CIRCULATIONAHA.107.739938. View

11.

Mogi C, Tobo M, Tomura H, Murata N, He X, Sato K . Involvement of proton-sensing TDAG8 in extracellular acidification-induced inhibition of proinflammatory cytokine production in peritoneal macrophages. J Immunol. 2009; 182(5):3243-51. DOI: 10.4049/jimmunol.0803466. View

12.

Parkes D, Pittner R, Jodka C, Smith P, Young A . Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism. 2001; 50(5):583-9. DOI: 10.1053/meta.2001.22519. View

13.

Azuma K, Watada H, Niihashi M, Otsuka A, Sato F, Kawasumi M . A new En face method is useful to quantitate endothelial damage in vivo. Biochem Biophys Res Commun. 2003; 309(2):384-90. DOI: 10.1016/j.bbrc.2003.08.013. View

14.

Chong Y, Shin S, Lee H, Kang J, Suh Y . Molecular mechanisms underlying cyclic AMP inhibition of macrophage dependent TNF-alpha production and neurotoxicity in response to amyloidogenic C-terminal fragment of Alzheimer's amyloid precursor protein. J Neuroimmunol. 2002; 133(1-2):160-74. DOI: 10.1016/s0165-5728(02)00349-1. View

15.

Aiello R, Bourassa P, Lindsey S, Weng W, Natoli E, Rollins B . Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 1999; 19(6):1518-25. DOI: 10.1161/01.atv.19.6.1518. View

16.

Izeboud C, Monshouwer M, van Miert A, Witkamp R . The beta-adrenoceptor agonist clenbuterol is a potent inhibitor of the LPS-induced production of TNF-alpha and IL-6 in vitro and in vivo. Inflamm Res. 1999; 48(9):497-502. DOI: 10.1007/s000110050493. View

17.

Delgado M, Gonzalez-Rey E, Ganea D . The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol. 2005; 175(11):7311-24. DOI: 10.4049/jimmunol.175.11.7311. View

18.

Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S . Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004; 24(11):2137-42. DOI: 10.1161/01.ATV.0000143933.20616.1b. View

19.

Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. DOI: 10.1056/NEJM199901143400207. View

20.

Kolterman O, Buse J, Fineman M, Gaines E, Heintz S, Bicsak T . Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88(7):3082-9. DOI: 10.1210/jc.2002-021545. View